gliptin

gliptin

Any of a class of drugs that are inhibitors of the enzyme dipeptidyl peptidase-4 (DPP-4). Members of this class include sitagliptin and saxagliptin and are used to treat type 2 diabetes mellitus. Synonym: dipeptidyl peptidase-4 inhibitor
References in periodicals archive ?
In addition to the gliptin effect on endothelial regeneration via the SDF1-CXCR4 axis in the Glp1[r.sup.-/-] mouse model, we demonstrated a direct proregenerative effect of SDF1 on human vascular endothelial cells (HUVECs) using a scratch assay.
Our data therefore underline the therapeutic potential of gliptin treatment after acute vascular injury that occurs in vascular diseases or vascular interventional therapies.
Kalra, "Choosing a gliptin," Indian Journal of Endocrinology and Metabolism, vol.
Several authors have been postulating that gliptins could theoretically avoid or delay diabetic complications [40,169-170], namely, due to reduction of oxidative stress and inflammation, as well as by antiapoptotic and pro-proliferative properties on various organs and tissues, including the kidney [101-103, 138, 171, 172].
Krooller-Schoon et al., "Gliptin and GLP-1 analog treatment improves survival and vascular inflammation/dysfunction in animals with lipopolysaccharide-induced endotoxemia," Basic Research in Cardiology, vol.
Thus the launch of these 2 products will lower the daily cost of treatment for a Diabetes patient on gliptin therapy by about 55%.
Some of the new DPP-4 inhibitors--the gliptin class of hypoglycemics--can interact with antiretrovirals.
Choosing a gliptin. Indian Journal of Endocrinology and Metabolism, 15(4), 298-308.
A gliptin is an excellent option in an obese patient with type 2 diabetes whose [HbA.sub.1c] is in the range of 7.6% on maximum-dose metformin and who is adamant about reaching the target [HbA.sub.1c] of 7.0% or less without gaining weight or taking injections.
Usually, we prescribe drugs such as metfornin, gliptin and byetta which balances the weight gain side effects of antidiabetic drugs," says Dr Ambrish Mittal, chairman, Endocrinology, Medanta - The Medicity.
Merck also markets sita- gliptin as Januvia for the same disease.
GLP-1-based therapeutic strategies have an increasing role in T2D treatment and consist of GLP-1 agonists and dipeptidyl peptidase-IV (DPP-IV) inhibitors (gliptins) [13].